A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Comparison of Ga-68-DOTA-Siglec-9 and F-18-Fluorodeoxyribose-Siglec-9: Inflammation Imaging and Radiation Dosimetry
Tekijät: Virtanen H, Silvola JMU, Autio A, Li XG, Liljenback H, Hellberg S, Siitonen R, Stahle M, Kakela M, Airaksinen AJ, Helariutta K, Tolvanen T, Veres TZ, Saraste A, Knuuti J, Jalkanen S, Roivainen A, Roivainen A
Kustantaja: WILEY-HINDAWI
Julkaisuvuosi: 2017
Journal: Contrast Media and Molecular Imaging
Tietokannassa oleva lehden nimi: CONTRAST MEDIA & MOLECULAR IMAGING
Lehden akronyymi: CONTRAST MEDIA MOL I
Artikkelin numero: UNSP 7645070
Sivujen määrä: 10
ISSN: 1555-4309
DOI: https://doi.org/10.1155/2017/7645070
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/29293117
Sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) is a ligand of inflammation-inducible vascular adhesion protein-1 (VAP1). We compared Ga-68-DOTA-and F-18-fluorodeoxyribose-(FDR) labeled Siglec-9motif peptides for PET imaging of inflammation. Methods. Firstly, we examined Ga-68-DOTA-Siglec-9 and F-18-FDR-Siglec-9 in rats with skin/muscle inflammation. We then studied F-18-FDR-Siglec-9 for the detection of inflamed atherosclerotic plaques in mice and compared it with previous Ga-68-DOTA-Siglec-9 results. Lastly, we estimated human radiation dosimetry fromthe rat data. Results. In rats, Ga-68-DOTA-Siglec-9 (SUV, 0.88 +/- 0.087) and F-18-FDR-Siglec-9 (SUV, 0.77 +/- 0.22) showed comparable (P = 0.29) imaging of inflammation. In atherosclerotic mice, 18 FFDR- Siglec-9 detected inflamed plaques with a target-to-background ratio (1.6 1/8 0.078) similar to previously tested Ga-68-DOTASiglec- 9 (P = 0.35). Humaneffectivedose estimates for Ga-68-DOTA-Siglec-9 and (18) F-FDR-Siglec-9were 0.024 and 0.022 mSv/MBq, respectively. Conclusion. Both tracers are suitable for PET imaging of inflammation. The easier production and lower cost of (68)GaDOTA-Siglec-9 present advantages over F-18-FDR-Siglec-9, indicating it as a primary choice for clinical studies.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
